Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?
We discuss these issues on October 5th 2021 from 2.00pm on, during the Virtual Symposium organized by the Interreg European project "Epigenetics of Immunity in Cancer".
- Date: 05.10.2021, From 2:00 pm
- Place: Zoom
- Typology: Virtual Symposium
October 5th 2021 - from 2.00 pm - Virtual Symposium - "Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?"
The Epigenetics of Immunity in Cancer (EPIC) project, funded by ERDF / Interreg V-A Italy-Austria 2014-2020 (ITAT1054), aims to improve the effectiveness of existing cancer therapies by utilizing specific compounds that elicit an immune response against tumors. Cancer cells undergo epigenetic changes that allow them to pass undetected by the immune system and keep proliferating. With the use of histone deacetylase inhibitors, we focus on reverting those epigenetic changes, restoring the expression of genes that allow cancer cells to be once again sensible to therapy and be recognized by the immune response.
This EPIC symposium features dedicated information on several aspects of the interaction between histone deacetylases, their inhibitors and the immune system. Five international scientists will present ongoing research and share insights on cancer epigenetics - specific attention will be given to MEF2, a class of transcription factors strictly connected to histone deacetylase activity in driving the epigenetic changes in cancer cells.
The symposium is free of charge and will be held via Zoom. In order to attend it, please register by sending an email to firstname.lastname@example.org indicating: I would like to attend to the Fall EPIC symposium entitled "Can we target the MEF2-class IIa HDACs axis to sustain immunotherapy?"
Download the program
Other News & Events
14 October 2021
EPIC at the NOI project fair
The yearly EFRE project fair on October 22nd is the perfect opportunity to meet us, we are presenting EPIC at booth 13.
13 October 2021
CHRIS COVID-19 study protocol available to the scientific community
Available in Open Access, it represents a resource for researchers who want to replicate similar studies.
28 September 2021
New headquarters for the Institute for Biomedicine
From mid-2022, the Institute for Biomedicine will open its new headquarters in the NOI Techpark: the interview with our director Peter P. Pramstaller.
24 August 2021
Covid-19 in Val Gardena
Uno studio dell’Azienda Sanitaria e di Eurac Research individua diversi fattori legati alla positività a Covid-19. La ricerca si è svolta nella primavera 2020 in Val Gardena (BZ).
08 July 2021
Large genomic analysis highlights COVID-19 risk factors
A new worldwide study published in Nature reveals 13 loci that are strongly associated with infection or severe COVID-19. The Institute of Biomedicine contributed data from the CHRIS Covid 19 study ...
21 June 2021
We are Social
The Institute of Biomedicine opens its own social channel. Follow us on Twitter.
07 June 2021
Sequencing of SARS-CoV-2 variants
Our laboratories work alongside the South Tyrolean Health Authority to track and monitor variants of the SARS-CoV-2 virus.